Abraxane (nab-paclitaxel) plus gemcitabine shown to improve survival in metastatic pancreatic cancer
Celgene UK and Ireland, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that its phase III clinical trial of ABRAXANE® (nab-paclitaxel) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with metastatic pancreatic cancer (who…